Table 2.
Base-case results from the Markov model, based on 5000 simulations
| Crizotinib Arm | Chemotherapy Arm | Incremental | |
|---|---|---|---|
| COSTS | $288,945 | $78,071 | $210,874 |
| Testing | $7215 | $0 | $7215 |
| PFS - First line | $246,127 | $31,218 | $214,909 |
| Progressed - Second line | $11,879 | $22,894 | -$11,015 |
| Progressed - Third line | $12,345 | $13,959 | -$1614 |
| Palliation | $11,379 | $10,001 | $1379 |
| LIFE YEARS (LYs) | 3.349 | 2.465 | 0.885 |
| PFS - First line | 2.256 | 1.735 | 0.521 |
| Progressed - Second line | 0.680 | 0.288 | 0.392 |
| Progressed - Third line | 0.155 | 0.175 | −0.020 |
| Palliation | 0.258 | 0.267 | −0.009 |
| QALYS | 2.541 | 1.769 | 0.772 |
| PFS - First line | 1.819 | 1.337 | 0.482 |
| Progressed - Second line | 0.449 | 0.190 | 0.259 |
| Progressed - Third line | 0.102 | 0.115 | −0.013 |
| Palliation | 0.170 | 0.126 | 0.044 |
| ICER (Cost per LY gained) | $238,394 | ||
| ICER (Cost per QALY gained) | $273,286 | ||
ICER Incremental cost effectiveness ratio, PFS Progression-free survival, QALY Quality adjusted life year